I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 32.61 M, beating the estimate of USD 29.21 M.
EPS: As of FY2026 Q2, the actual value is USD 0.24.
EBIT: As of FY2026 Q2, the actual value is USD 3.38 M.
Second Quarter 2026 Financial Highlights
Anika Therapeutics, Inc. reported total revenue of $32.6 million for the second quarter of 2026, an increase of 16% compared to $28.2 million in the prior-year period. Gross profit for the quarter was $21.2 million, up from $14.4 million in the prior-year period, with the gross margin expanding to 65%. Total operating expenses were $18.3 million, compared to $18.5 million in the prior-year period, and adjusted operating expenses, excluding $0.8 million of one-time severance-related expenses, declined 6% year-over-year to $17.5 million. Net income for the second quarter was $3.3 million, representing a 10% margin, a significant improvement from - $3.970 million in the prior-year period. Adjusted EBITDA reached $7.1 million, an increase from - $0.188 million in the prior-year period, with an Adjusted EBITDA margin of 22%. As of June 30, 2026, cash and cash equivalents stood at $38.4 million.
Segment Revenue (Second Quarter 2026)
- Commercial Channel Revenue: Increased 17% year-over-year to a record $13.9 million.
- OEM Channel Revenue: Was $18.705 million, up 14% from $16.340 million in the prior-year period.
- International Revenue: Reached a record $12.6 million, increasing 22% year-over-year.
Six Months Ended June 30, 2026 Financial Highlights
For the six months ended June 30, 2026, Anika Therapeutics, Inc. reported total revenue of $62.222 million, a 14% increase from $54.387 million in the prior-year period. Gross profit was $40.241 million, compared to $29.044 million in the prior-year period. Total operating expenses were $42.775 million, up from $37.508 million in the prior-year period. The net loss for the six months was - $1.747 million, an improvement from - $8.843 million in the prior-year period. Adjusted EBITDA for the six months was $11.380 million, compared to - $0.061 million in the prior-year period. Net cash provided by operating activities for the six months was - $5.530 million, compared to - $0.319 million in the prior-year period.
Operational Metrics (Six Months Ended June 30, 2026)
- Integrity Global Units: Increased both sequentially and year-over-year during the second quarter of 2026, with year-to-date sales growing 39% year-over-year.
Outlook / Guidance
Anika Therapeutics, Inc. raised its fiscal year 2026 outlook, projecting total company revenue growth of 5% to 10% and an adjusted EBITDA margin of 13% to 17%. For fiscal year 2027, the company forecasts total company revenue growth of flat to 5%, with Commercial Channel revenue growth of 5% to 15% and OEM revenue growth expected to be flat to modestly lower. This updated guidance for 2027 reflects a new practice to include only revenue from products that have received regulatory approval or clearance, leading to the exclusion of Hyalofast revenue from the Commercial Channel guidance.